EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

被引：904

作者：

Choi, Young Lim ^{[1
,2
]}

Soda, Manabu ^{[1
]}

Yamashita, Yoshihiro ^{[1
]}

Ueno, Toshihide ^{[1
]}

Takashima, Junpei ^{[3
]}

Nakajima, Takahiro ^{[4
]}

Yatabe, Yasushi ^{[5
]}

Takeuchi, Kengo ^{[7
]}

Hamada, Toru ^{[1
]}

Haruta, Hidenori ^{[1
]}

Ishikawa, Yuichi ^{[8
]}

Kimura, Hideki ^{[4
]}

Mitsudomi, Tetsuya ^{[6
]}

Tanio, Yoshiro ^{[3
]}

Mano, Hiroyuki ^{[1
,2
,9
]}

机构：

[1] Jichi Med Univ, Div Funct Genom, Shimotsuke, Tochigi 3290498, Japan

[2] Univ Tokyo, Grad Sch Med, Dept Med Genom, Tokyo, Japan

[3] Osaka Gen Med Ctr, Dept Internal Med, Osaka, Japan

[4] Chiba Canc Ctr, Div Thorac Dis, Chiba 2608717, Japan

[5] Aichi Canc Ctr Hosp, Dept Pathol, Aichi, Japan

[6] Aichi Canc Ctr Hosp, Dept Thorac Surg, Aichi, Japan

[7] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo 170, Japan

[8] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo 170, Japan

[9] Japan Sci & Technol Agcy, Saitama, Japan

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 363卷 / 18期

基金：

日本学术振兴会;

关键词：

CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; ACQUIRED-RESISTANCE; IMATINIB; IDENTIFICATION; GEFITINIB; FUSION; DOMAIN; ABL; EFFICACY;

D O I：

10.1056/NEJMoa1007478

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non-small-cell lung cancers, and clinical trials of specific inhibitors of ALK for the treatment of such tumors are currently under way. Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor. Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.

引用

页码：1734 / 1739

页数：6

共 20 条

[1] Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors [J].

Bossi, Roberto T. ;

Saccardo, M. Beatrice ;

Ardini, Elena ;

Menichincheri, Maria ;

Rusconi, Luisa ;

Magnaghi, Paola ;

Orsini, Paolo ;

Avanzi, Nilla ;

Borgia, Andrea Lombardi ;

Nesi, Marcella ;

Bandiera, Tiziano ;

Fogliatto, Gianpaolo ;

Bertrand, Jay A. .

BIOCHEMISTRY, 2010, 49 (32) :6813-6825

[2] Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? [J].

Branford, Susan ;

Melo, Junia V. ;

Hughes, Timothy P. .

BLOOD, 2009, 114 (27) :5426-5435

[3] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

[4] Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer [J].

Choi, Young Lim ;

Takeuchi, Kengo ;

Soda, Manabu ;

Inamura, Kentaro ;

Togashi, Yuki ;

Hatano, Satoko ;

Enomoto, Munehiro ;

Hamada, Toru ;

Haruta, Hidenori ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Ueno, Toshihide ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Sugiyama, Yukihiko ;

Ishikawa, Yuichi ;

Mano, Hiroyuki .

CANCER RESEARCH, 2008, 68 (13) :4971-4976

[5] Identification of a constitutively active mutant of JAK3 by retroviral expression screening [J].

Choi, Young Lim ;

Kaneda, Ruri ;

Wada, Tomoaki ;

Fujiwara, Shin-ichiro ;

Soda, Manabu ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Enomoto, Munehiro ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Mano, Hiroyuki .

LEUKEMIA RESEARCH, 2007, 31 (02) :203-209

[6] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[7] The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].

Deininger, M ;

Buchdunger, E ;

Druker, BJ .

BLOOD, 2005, 105 (07) :2640-2653

[8] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[9] Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1 [J].

Hindie, Valerie ;

Stroba, Adriana ;

Zhang, Hua ;

Lopez-Garcia, Laura A. ;

Idrissova, Leila ;

Zeuzem, Stefan ;

Hirschberg, Daniel ;

Schaeffer, Francis ;

Jorgensen, Thomas J. D. ;

Engel, Matthias ;

Alzari, Pedro M. ;

Biondi, Ricardo M. .

NATURE CHEMICAL BIOLOGY, 2009, 5 (10) :758-764

[10] EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer [J].

Horn, Leora ;

Pao, William .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4232-4235

← 1 2 →